Financial Services - Finland



Char

**Buy** (old: Buy) 17.11.2023 **EUR 11.00** (old: EUR 11.00)

### Solid Q3 // Fully on track to reach guidance; chg

Yesterday, Multitude published Q3'23 figures. While current trading remained solid, the ongoing tight cost control is bearing fruit, visible in the ongoing strong bottom line:

- Sales came in at € 57.9m (4% qoq, 7% yoy) is broadly in line with our estimates of € 58.9m, driven by
  the strong growth of the lending portfolio to 548m (5% qoq, 8% yoy). Importantly all three tribes contributed to the growth (ferratum tribe: € 46.8m, 4% qoq, 3% yoy; CapitalBox: € 5.5m, 5% qoq, 23%
  yoy; sweep: € 5.0m, 6% qoq, 30% yoy).
- EBIT increased by 27% yoy to € 11.6m (4% qoq), in line with our estimate of € 12.2m. The strength resulted from ongoing tight cost control (personnel: +6% yoy; other operating expenses: -6% yoy) and a further growing loan book at stable margins that is driving top line. As interest expenses came in as expected at € 6.4m (21% qoq, 79% yoy vs. eNuW: € 6.5m), EBT increased by 13% yoy to € 5.8m.

With another solid quarter in the books, **Multitude is still seen well on track to reach its FY23 EBIT guidance** of  $\in$  45m (vs eNuW:  $\in$  44.6m, 41% yoy). Further sequential growth of the net loan book in Q4 to  $\in$  560m until eoy, combined with ongoing tight cost control should allow to reach the goal with an implied EBIT margin of 19%. Expecting a further moderate sequential increase of interest expenses, we see EPS to stand at  $\in$  0.65 at YE.

In a nutshell, Multitude should remain a growing company with perspectively three profit centers within the Group (currently two: ferratum and CapitalBox). The **strategic transition from a near prime loan provider to a prime loan provider** bode well for the company and should continue to eliminate risks, further stabilizing operations and profits. More details should be provided during the **CMD next Tuesday**.

The stock is still **heavily mispriced**, **trading at negative EV** and a 3.3x PE'23, completely neglecting the promising guidance for 2023e and 2024e and the earnings potential.

Importantly, Union Investment announced earlier this week to have **reduced its position to below 5% from >10%**. This share overhang that burdened the stock over last quarters should now be rather off the table and should provide tailwind for the stock.

BUY with an unchanged € 11 PT, based on our residual income model.

Y/E 31.12 (EUR m)	2020	2021	2022	2023e	2024e	2025e
Sales	230.5	204.2	212.4	227.8	262.6	295.8
Sales growth	-21.4%	-11.4%	4.0%	7.2%	15.3%	12.6%
EBITDA	41.9	42.5	49.1	60.4	75.5	91.1
Net debt (if net cash=0)	-61.5	-111.6	-97.7	-109.6	-134.6	-168.9
FCF	127.8	60.2	-19.2	0.6	1.3	13.4
Net Debt/EBITDA	0.0	0.0	0.0	0.0	0.0	0.0
EPS pro forma	0.23	0.11	0.56	0.82	1.26	1.69
EBITDA margin	18.2%	20.8%	23.1%	26.5%	28.8%	30.8%
ROCE	4.9%	3.7%	4.0%	5.7%	6.8%	7.9%
EV/sales	-0.1	-0.3	-0.2	-0.4	-0.3	-0.4
EV/EBITDA	-0.3	-1.3	-0.9	-1.4	-1.1	-1.3
PER	11.7	24.7	4.8	3.3	2.1	1.6
Adjusted FCF yield	-313.9%	-38.3%	-42.4%	-44.2%	-45.2%	-42.7%

Source: Company data, NuWays, Close price as of 13.11.2023



Market data					
Share price (in €)	2.68				
Market cap (in € m)	57.8				
Number of shares (in m pcs)	21.6				
Enterprise value (in € m)					
Ø trading volume (6 months)	2,259				


	Identifier
Bloomberg	FRU GR
Reuters	FRU
WKN	A1W9NS
ISIN	FI4000106299


Key shareholders				
Jorma Jokela	55.2%			
Universal	4.9%			
Dorval	4.8%			
Ferratum Oyj	0.7%			


Estimates changes					
	<u>2023e</u>	<u>2024e</u>	<u>2025e</u>		
Sales	-0%	-0%	-1%		
EBIT	-2%	-2%	-1%		
EPS	-5%	-1%	-1%		

### Comment on changes

Minor changes to reflect Q2'23 figures







### Company description

As a pioneer in digital banking solutions, Multitude is a global service provider for developing and operating a global financial platform and offering real-time scoring, lending and banking services to consumers and companies.

### Guidance

- EBIT FY23: € 45m
- EBIT FY24: € 67.5m

Update - 17.11.2023



# **Financials**

Profit and loss (EUR m)	2020	2021	2022	2023e	2024e	2025e
Sales	230.5	204.2	212.4	227.8	262.6	295.8
Sales growth	-21.4%	-11.4%	4.0%	7.2%	15.3%	12.6%
Cost of sales	91.0	71.9	78.7	83.1	88.9	95.1
Gross profit	139.5	132.3	133.7	144.7	173.7	200.7
Sales and marketing	22.7	15.6	12.2	14.9	17.0	19.1
General and administration	33.1	33.0	34.0	34.3	39.4	43.9
Research and development	0.0	0.0	0.0	0.0	0.0	0.0
Other operating income	0.5	-0.6	-0.6	0.2	0.3	0.3
Other operating expenses	42.3	40.4	37.8	35.3	42.0	46.9
Total operating expenses	97.6	89.7	84.6	84.3	98.2	109.6
Unusual or infrequent items	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	41.9	42.5	49.1	60.4	75.5	91.1
Depreciation	3.2	2.9	2.6	2.3	2.6	3.0
EBITA	38.7	39.6	46.5	58.1	72.9	88.1
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	10.2	12.4	14.9	13.6	15.6	17.6
Impairment charges	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	28.5	27.2	31.6	44.6	57.3	70.5
Interest income	0.5	3.6	0.5	2.1	1.6	1.9
Interest expenses	22.8	26.1	18.2	25.4	27.6	30.3
Investment income	0.0	0.0	0.0	0.0	0.0	0.0
Financial result	-22.3	-22.5	-17.8	-23.3	-25.9	-28.4
Recurring pretax income from continuing operations	6.2	4.7	13.8	21.3	31.3	42.1
Extraordinary income/loss	0.0	0.0	0.0	0.0	0.0	0.0
Earnings before taxes	6.2	4.7	13.8	21.3	31.3	42.1
Income tax expense	1.3	2.4	1.8	3.6	4.2	5.6
Net income from continuing operations	5.0	2.3	12.0	17.7	27.2	36.5
Income from discontinued operations (net of tax)	4.5	5.8	0.0	0.0	0.0	0.0
Net income	0.5	-6.8	8.3	14.0	23.5	32.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0
Net profit (reported)	0.5	-6.8	8.3	14.0	23.5	32.9
Average number of shares	21.6	21.6	21.6	21.6	21.6	21.6
•					4 00	4 = 0
•	0.02	-0.32	0.39	0.65	1.09	1.52
EPS reported	0.02	-0.32	0.39			
Profit and loss (common size)	0.02 2020	-0.32 2021	0.39	2023e	2024e	2025e
EPS reported  Profit and loss (common size)  Sales	0.02 2020 100.0%	-0.32 2021 100.0%	0.39 2022 100.0%	2023e 100.0%	2024e 100.0%	2025e 100.0%
EPS reported  Profit and loss (common size)  Sales  Cost of sales	2020 100.0% 39.5%	-0.32 2021 100.0% 35.2%	0.39 2022 100.0% 37.0%	2023e 100.0% 36.5%	2024e 100.0% 33.8%	2025e 100.0% 32.2%
EPS reported  Profit and loss (common size)  Sales  Cost of sales  Gross profit	2020 100.0% 39.5% 60.5%	-0.32 2021 100.0% 35.2% 64.8%	0.39 2022 100.0% 37.0% 63.0%	2023e 100.0% 36.5% 63.5%	2024e 100.0% 33.8% 66.2%	2025e 100.0% 32.2% 67.8%
EPS reported  Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing	2020 100.0% 39.5% 60.5% 9.8%	-0.32 2021 100.0% 35.2% 64.8% 7.7%	0.39 2022 100.0% 37.0% 63.0% 5.7%	2023e 100.0% 36.5% 63.5% 6.6%	2024e 100.0% 33.8% 66.2% 6.5%	2025e 100.0% 32.2% 67.8% 6.5%
EPS reported  Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration	2020 100.0% 39.5% 60.5% 9.8% 14.4%	-0.32 2021 100.0% 35.2% 64.8% 7.7% 16.2%	0.39 2022 100.0% 37.0% 63.0% 5.7% 16.0%	2023e 100.0% 36.5% 63.5% 6.6% 15.0%	2024e 100.0% 33.8% 66.2% 6.5% 15.0%	2025e 100.0% 32.2% 67.8% 6.5% 14.8%
EPS reported  Profit and loss (common size)  Sales Cost of sales Gross profit Sales and marketing General and administration Research and development	2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0%	-0.32 2021 100.0% 35.2% 64.8% 7.7% 16.2% 0.0%	0.39 2022 100.0% 37.0% 63.0% 5.7% 16.0% 0.0%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0%
EPS reported  Profit and loss (common size)  Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income	2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2%	-0.32 2021 100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3%	0.39 2022 100.0% 37.0% 63.0% 5.7% 16.0% 0.0% -0.3%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 0.1%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1%
Profit and loss (common size)  Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses	2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3%	-0.32 2021 100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8%	0.39  2022  100.0%  37.0%  63.0%  5.7%  16.0%  0.0%  -0.3%  17.8%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 0.1% 15.5%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8%
Profit and loss (common size)  Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses	0.02 2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4%	-0.32 2021 100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9%	0.39  2022  100.0%  37.0%  63.0%  5.7%  16.0%  0.0%  -0.3%  17.8%  39.8%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0%
Profit and loss (common size)  Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses EBITDA	0.02  2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2%	-0.32  2021  100.0%  35.2%  64.8%  7.7%  16.2%  0.0%  -0.3%  19.8%  43.9%  20.8%	0.39  2022  100.0% 37.0% 63.0% 5.7% 16.0% 0.0% -0.3% 17.8% 39.8% 23.1%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0% 26.5%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0%
EPS reported  Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation	0.02  2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4%	-0.32  2021 100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9% 20.8% 1.4%	0.39  2022  100.0%  37.0%  63.0%  5.7%  16.0%  0.0%  -0.3%  17.8%  39.8%  23.1%  1.2%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0% 26.5% 1.0%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 30.8% 1.0%
EPS reported  Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA	0.02  2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4% 16.8%	-0.32  2021  100.0%  35.2%  64.8%  7.7%  16.2%  0.0%  -0.3%  19.8%  43.9%  20.8%  1.4%  19.4%	0.39  2022  100.0%  37.0%  63.0%  5.7%  16.0%  0.0%  -0.3%  17.8%  39.8%  23.1%  1.2%  21.9%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0% 26.5% 1.0% 25.5%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 30.8% 1.0% 29.8%
EPS reported  Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill	0.02  2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4% 16.8% 0.0%	-0.32  2021  100.0%  35.2%  64.8%  7.7%  16.2%  0.0%  -0.3%  19.8%  43.9%  20.8%  1.4%  19.4%  0.0%	0.39  2022 100.0% 37.0% 63.0% 5.7% 16.0% -0.3% 17.8% 39.8% 23.1% 1.2% 21.9% 0.0%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 30.8% 1.0% 29.8% 0.0%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill  Amortisation of intangible assets	0.02  2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4% 16.8% 0.0% 4.4%	-0.32  2021 100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9% 20.8% 1.4% 19.4% 0.0% 6.1%	0.39  2022 100.0% 37.0% 63.0% 5.7% 16.0% -0.3% 17.8% 39.8% 23.1% 1.2% 21.9% 0.0% 7.0%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0% 6.0%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0% 6.0%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 30.8% 1.0% 29.8% 0.0% 6.0%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges	0.02  2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4% 16.8% 0.0% 4.4% 0.0%	-0.32  2021  100.0%  35.2%  64.8%  7.7%  16.2%  0.0%  -0.3%  19.8%  43.9%  20.8%  1.4%  0.0%  6.1%  0.0%	0.39  2022 100.0% 37.0% 63.0% 5.7% 16.0% -0.3% 17.8% 39.8% 23.1% 1.2% 21.9% 0.0% 7.0% 0.0%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0% 6.0% 0.0%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0% 6.0% 0.0%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 30.8% 1.0% 29.8% 0.0% 6.0% 0.0%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)	0.02  2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4% 16.8% 0.0% 4.4% 0.0% 12.4%	-0.32  2021  100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9% 20.8% 1.4% 0.0% 6.1% 0.0% 13.3%	0.39  2022  100.0%  37.0%  63.0%  5.7%  16.0%  -0.3%  17.8%  39.8%  23.1%  1.2%  21.9%  0.0%  7.0%  0.0%  14.9%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.1% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0% 6.0% 0.0%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0% 6.0% 0.0% 21.8%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 30.8% 0.0% 6.0% 0.0% 23.8%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income	0.02  2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4% 16.8% 0.0% 4.4% 0.0% 12.4% 0.2%	-0.32  2021 100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9% 20.8% 1.4% 0.0% 6.1% 0.0% 13.3% 1.8%	0.39  2022 100.0% 37.0% 63.0% 5.7% 16.0% -0.3% 17.8% 39.8% 23.1% 1.2% 21.9% 0.0% 7.0% 0.0% 14.9% 0.2%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0% 6.0% 0.0% 19.6%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0% 6.0% 0.0% 21.8%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 30.8% 0.0% 6.0% 0.0% 23.8% 0.6%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses	0.02  2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4% 16.8% 0.0% 4.4% 0.0% 12.4% 0.2% 9.9%	-0.32  2021  100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9% 20.8% 1.4% 0.0% 6.1% 0.0% 13.3% 1.8% 12.8%	0.39  2022 100.0% 37.0% 63.0% 5.7% 16.0% -0.3% 17.8% 39.8% 23.1% 1.2% 21.9% 0.0% 7.0% 0.0% 14.9% 0.2% 8.6%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0% 6.0% 0.0% 19.6% 0.9% 11.2%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0% 6.0% 0.0% 21.8% 0.6% 10.5%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 29.8% 0.0% 6.0% 0.0% 23.8% 0.6% 10.2%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income	0.02  2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4% 16.8% 0.0% 4.4% 0.0% 12.4% 0.2% 9.9% 0.0%	-0.32  2021  100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9% 20.8% 1.4% 0.0% 6.1% 0.0% 13.3% 1.8% 12.8% 0.0%	0.39  2022 100.0% 37.0% 63.0% 5.7% 16.0% -0.3% 17.8% 39.8% 23.1% 1.2% 21.9% 0.0% 7.0% 0.0% 14.9% 0.2% 8.6% 0.0%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0% 6.0% 0.9% 11.2% 0.0%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0% 6.0% 0.0% 21.8% 0.6% 10.5% 0.0%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 29.8% 0.0% 6.0% 0.0% 23.8% 0.6% 10.2% 0.0%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income  Financial result	0.02  2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4% 16.8% 0.0% 4.4% 0.0% 12.4% 0.2% 9.9% 0.0% neg.	-0.32  2021  100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9% 20.8% 1.4% 0.0% 6.1% 0.0% 13.3% 1.8% 12.8% 0.0% neg.	0.39  2022 100.0% 37.0% 63.0% 5.7% 16.0% -0.3% 17.8% 39.8% 23.1% 1.2% 21.9% 0.0% 7.0% 0.0% 14.9% 0.2% 8.6% 0.0% neg.	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0% 6.0% 0.0% 19.6% 0.9% 11.2% 0.0% neg.	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0% 6.0% 0.0% 21.8% 0.6% 10.5% 0.0% neg.	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 29.8% 0.0% 6.0% 0.0% 23.8% 0.6% 10.2% 0.0% neg.
EPS reported  Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income  Financial result  Recurring pretax income from continuing operations	0.02  2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4% 16.8% 0.0% 4.4% 0.0% 12.4% 0.2% 9.9% 0.0% neg. 2.7%	-0.32  2021 100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9% 20.8% 1.4% 0.0% 6.1% 0.0% 13.3% 1.8% 12.8% 0.0% neg. 2.3%	0.39  2022 100.0% 37.0% 63.0% 5.7% 16.0% -0.3% 17.8% 39.8% 23.1% 1.2% 21.9% 0.0% 7.0% 0.0% 14.9% 0.2% 8.6% 0.0% neg. 6.5%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0% 6.0% 0.0% 19.6% 0.9% 11.2% 0.0% neg. 9.3%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0% 6.0% 0.0% 10.5% 0.0% 10.5% 0.0% neg. 11.9%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 29.8% 0.0% 6.0% 0.0% 23.8% 0.6% 10.2% 0.0% neg. 14.2%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income  Financial result  Recurring pretax income from continuing operations  Extraordinary income/loss	0.02  2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 16.8% 0.0% 4.4% 0.0% 12.4% 0.2% 9.9% 0.0% neg. 2.7% 0.0%	-0.32  2021  100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9% 20.8% 1.4% 0.0% 6.1% 0.0% 13.3% 1.8% 12.8% 0.0% neg. 2.3% 0.0%	0.39  2022 100.0% 37.0% 63.0% 5.7% 16.0% -0.3% 17.8% 39.8% 23.1% 1.2% 21.9% 0.0% 7.0% 0.0% 14.9% 0.2% 8.6% 0.0% neg. 6.5% 0.0%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0% 6.0% 0.9% 11.2% 0.0% neg. 9.3% 0.0%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0% 6.0% 0.0% 10.5% 0.0% 10.5% 0.0% neg. 11.9% 0.0%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 30.8% 0.0% 6.0% 0.0% 23.8% 0.6% 10.2% 0.0% neg. 14.2% 0.0%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income  Financial result  Recurring pretax income from continuing operations  Extraordinary income/loss  Earnings before taxes	2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 16.8% 0.0% 4.4% 0.0% 12.4% 0.2% 9.9% 0.0% neg. 2.7%	-0.32  2021 100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9% 20.8% 1.4% 0.0% 6.1% 0.0% 13.3% 1.8% 12.8% 0.0% neg. 2.3% 0.0% 2.3%	0.39  2022 100.0% 37.0% 63.0% 5.7% 16.0% -0.3% 17.8% 39.8% 23.1% 1.2% 21.9% 0.0% 7.0% 0.0% 14.9% 0.2% 8.6% 0.0% neg. 6.5% 0.0% 6.5%	2023e 100.0% 36.5% 66.5% 6.6% 15.0% 0.0% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0% 6.0% 0.9% 11.2% 0.0% neg. 9.3% 0.0% 9.3%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0% 6.0% 0.0% 21.8% 0.6% 10.5% 0.0% neg. 11.9% 0.0%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 29.8% 0.0% 6.0% 0.0% 23.8% 0.6% 10.2% 0.0% neg. 14.2% 0.0%
EPS reported  Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income  Financial result  Recurring pretax income from continuing operations  Extraordinary income/loss  Earnings before taxes  Tax rate	2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4% 16.8% 0.0% 4.4% 0.0% 12.4% 0.2% 9.9% 0.0% neg. 2.7% 0.0% 2.7% 20.7%	-0.32  2021  100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9% 20.8% 1.4% 0.0% 6.1% 0.0% 13.3% 1.8% 12.8% 0.0% neg. 2.3% 0.0% 2.3% 50.2%	0.39  2022  100.0% 37.0% 63.0% 5.7% 16.0% -0.3% 17.8% 39.8% 23.1% 1.2% 21.9% 0.0% 7.0% 0.0% 14.9% 0.2% 8.6% 0.0% neg. 6.5% 0.0% 6.5% 13.3%	2023e 100.0% 36.5% 66.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0% 6.0% 0.0% 19.6% 0.9% 11.2% 0.0% neg. 9.3% 0.0% 9.3% 17.1%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0% 6.0% 0.0% 21.8% 0.6% 10.5% 0.0% neg. 11.9% 0.0% 11.9% 13.3%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 15.8% 37.0% 29.8% 0.0% 6.0% 0.0% 23.8% 0.6% 10.2% 0.0% neg. 14.2% 13.3%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income  Financial result  Recurring pretax income from continuing operations  Extraordinary income/loss  Earnings before taxes  Tax rate  Net income from continuing operations	2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4% 16.8% 0.0% 4.4% 0.0% 12.4% 0.2% 9.9% 0.0% neg. 2.7% 0.0% 20.7% 20.7%	-0.32  2021 100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9% 20.8% 1.4% 0.0% 6.1% 0.0% 13.3% 1.8% 12.8% 0.0% neg. 2.3% 0.0% 2.3% 50.2% 1.1%	0.39  2022 100.0% 37.0% 63.0% 5.7% 16.0% -0.3% 17.8% 39.8% 23.1% 1.2% 21.9% 0.0% 7.0% 0.0% 14.9% 0.2% 8.6% 0.0% neg. 6.5% 13.3% 5.6%	2023e 100.0% 36.5% 66.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0% 6.0% 0.0% 19.6% 0.9% 11.2% 0.0% neg. 9.3% 0.0% 9.3% 17.1% 7.8%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0% 6.0% 0.0% 21.8% 0.6% 10.5% 0.0% neg. 11.9% 0.0% 11.9% 13.3% 10.3%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 29.8% 0.0% 6.0% 0.0% 23.8% 0.6% 10.2% 0.0% neg. 14.2% 13.3% 12.4%
EPS reported  Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income  Financial result  Recurring pretax income from continuing operations  Extraordinary income/loss  Earnings before taxes  Tax rate  Net income	0.02  2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4% 16.8% 0.0% 4.4% 0.0% 12.4% 0.2% 9.9% 0.0% neg. 2.7% 0.0% 2.7% 20.7% 2.2% 0.2%	-0.32  2021  100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9% 20.8% 1.4% 0.0% 6.1% 0.0% 13.3% 1.8% 12.8% 0.0% neg. 2.3% 0.0% 2.3% 50.2% 1.1% -3.3%	0.39  2022 100.0% 37.0% 63.0% 5.7% 16.0% -0.3% 17.8% 39.8% 23.1% 1.2% 21.9% 0.0% 7.0% 0.0% 14.9% 0.2% 8.6% 0.0% neg. 6.5% 0.0% 6.5% 13.3% 5.6% 3.9%	2023e 100.0% 36.5% 63.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0% 6.0% 0.0% 19.6% 0.9% 11.2% 0.0% neg. 9.3% 0.0% 9.3% 17.1% 7.8% 6.1%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0% 6.0% 0.0% 21.8% 0.6% 10.5% 0.0% neg. 11.9% 13.3% 10.3% 8.9%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 29.8% 0.0% 6.0% 0.0% 0.0% 10.2% 0.0% neg. 14.2% 0.0% 13.3% 12.4% 11.1%
Profit and loss (common size)  Sales  Cost of sales  Gross profit  Sales and marketing  General and administration  Research and development  Other operating income  Other operating expenses  Total operating expenses  EBITDA  Depreciation  EBITA  Amortisation of goodwill  Amortisation of intangible assets  Impairment charges  EBIT (inc revaluation net)  Interest income  Interest expenses  Investment income  Financial result  Recurring pretax income from continuing operations  Extraordinary income/loss  Earnings before taxes  Tax rate  Net income from continuing operations	2020 100.0% 39.5% 60.5% 9.8% 14.4% 0.0% 0.2% 18.3% 42.4% 18.2% 1.4% 16.8% 0.0% 4.4% 0.0% 12.4% 0.2% 9.9% 0.0% neg. 2.7% 0.0% 20.7% 20.7%	-0.32  2021 100.0% 35.2% 64.8% 7.7% 16.2% 0.0% -0.3% 19.8% 43.9% 20.8% 1.4% 0.0% 6.1% 0.0% 13.3% 1.8% 12.8% 0.0% neg. 2.3% 0.0% 2.3% 50.2% 1.1%	0.39  2022 100.0% 37.0% 63.0% 5.7% 16.0% -0.3% 17.8% 39.8% 23.1% 1.2% 21.9% 0.0% 7.0% 0.0% 14.9% 0.2% 8.6% 0.0% neg. 6.5% 13.3% 5.6%	2023e 100.0% 36.5% 66.5% 6.6% 15.0% 0.0% 0.1% 15.5% 37.0% 26.5% 1.0% 25.5% 0.0% 6.0% 0.0% 19.6% 0.9% 11.2% 0.0% neg. 9.3% 0.0% 9.3% 17.1% 7.8%	2024e 100.0% 33.8% 66.2% 6.5% 15.0% 0.0% 0.1% 16.0% 37.4% 28.8% 1.0% 27.8% 0.0% 6.0% 0.0% 21.8% 0.6% 10.5% 0.0% neg. 11.9% 0.0% 11.9% 13.3% 10.3%	2025e 100.0% 32.2% 67.8% 6.5% 14.8% 0.0% 0.1% 15.8% 37.0% 30.8% 1.0% 29.8% 0.0% 6.0% 0.0% 23.8% 0.6% 10.2% 0.0% neg. 14.2% 13.3% 12.4%

Source: Company data, NuWays

Update - 17.11.2023



Balance sheet (EUR m)	2020	2021	2022	2023e	2024e	2025e
Intangible assets	38.9	35.8	31.4	30.4	29.4	28.4
Property, plant and equipment	8.1	5.0	7.7	7.2	6.7	6.2
Financial assets	5.0	6.2	28.9	40.9	40.9	40.9
FIXED ASSETS	52.0	47.1	68.0	78.5	77.0	75.5
Inventories	0.0	0.0	0.0	0.0	0.0	0.0
Accounts receivable	361.0	451.7	509.5	560.1	605.1	648.6
Other assets and short-term financial assets	17.6	15.9	15.7	15.7	15.7	15.7
Liquid assets	236.6	301.6	153.3	159.5	167.0	187.0
Deferred taxes	7.9	7.0	7.2	7.2	7.2	7.2
Deferred charges and prepaid expenses	0.0	1.3	1.5	1.5	1.5	1.5
CURRENT ASSETS	623.0	777.5	687.3	744.1	796.6	860.1
TOTAL ASSETS	675.1	824.5	755.2	822.6	873.6	935.6
SHAREHOLDERS EQUITY	125.6	174.8	182.0	204.3	227.8	260.7
MINORITY INTEREST	0.0	0.0	0.0	0.0	0.0	0.0
Provisions for pensions and similar obligations	0.0	0.0	0.0	0.0	0.0	0.0
Other provisions and accrued liabilities	0.0	0.0	0.0	0.0	0.0	0.0
Short-term liabilities to banks	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	9.9	1.4	6.3	6.3	6.3	6.3
Advance payments received on orders	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities (incl. from lease and rental contracts)	351.4	499.9	513.3	553.6	575.9	599.4
Deferred taxes	0.3	0.2	1.0	1.0	1.0	1.0
Deferred income	0.0	0.0	0.0	0.0	0.0	0.0
CURRENT LIABILITIES	361.4	501.4	519.6	559.9	582.3	605.7
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	675.1	824.6	755.2	822.6	873.6	935.6
Balance sheet (common size)	2020	2021	2022	2023e	2024e	2025e
Intangible assets	5.8%	4.3%	4.2%	3.7%	3.4%	3.0%
Property, plant and equipment	1.2%	0.6%	1.0%	0.9%	0.8%	0.7%
Financial assets	0.7%	0.8%	3.8%	5.0%	4.7%	4.4%
FIXED ASSETS	7.7%	5.7%	9.0%	9.5%	8.8%	8.1%
Inventories	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Accounts receivable	53.5%	54.8%	67.5%	68.1%	69.3%	69.3%
Other assets and short-term financial assets	2.6%	1.9%	2.1%	1.9%	1.8%	1.7%
Liquid assets	35.0%	36.6%	20.3%	19.4%	19.1%	20.0%
Deferred taxes	1.2%	0.8%	1.0%	0.9%	0.8%	0.8%
Deferred charges and prepaid expenses	0.0%	0.2%	0.2%	0.2%	0.2%	0.2%
CURRENT ASSETS	92.3%	94.3%	91.0%	90.5%	91.2%	91.9%
TOTAL ASSETS	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
SHAREHOLDERS EQUITY	18.6%	21.2%	24.1%	24.8%	26.1%	27.9%
•	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
MINORITY INTEREST						
Provisions for pensions and similar obligations	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other provisions and accrued liabilities	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Short-term liabilities to banks	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Accounts payable	1.5%	0.2%	0.8%	0.8%	0.7%	0.7%
Advance payments received on orders	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other liabilities (incl. from lease and rental contracts)	52.1%	60.6%	68.0%	67.3%	65.9%	64.1%
Deferred taxes	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%
Deferred income	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CURRENT LIABILITIES	53.5%	60.8%	68.8%	68.1%	66.7%	64.7%
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Source: Company data, NuWays

Update - 17.11.2023



Cash flow statement (EUR m)	2020	2021	2022	2023e	2024e	20256
Net profit/loss	0.5	-3.5	12.0	14.0	23.5	32.9
Depreciation of fixed assets (incl. leases)	3.2	3.7	3.2	2.3	2.6 15.6	3.0
Amortisation of goodwill & intangible assets	10.2 -2.3	13.5	15.0 -3.7	13.6	0.0	17.6
Others	-2.3 127.0	-3.3 54.5	-3. <i>1</i> -26.5	0.0	-0.2	0.0 11.9
Cash flow from operating activities				-0.9		
Increase/decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0
Increase/decrease in accounts receivable	-69.3	-152.9	-137.3	-129.4	-133.9	-138.6
Increase/decrease in accounts payable	-13.2	-12.6	-0.5	-1.0	-1.0	-1.0
Increase/decrease in other working capital positions	97.4	145.4	17.8	40.3	22.4	23.5
Increase/decrease in working capital	14.9	-20.0	-119.9	-90.1	-112.6	-116.1
Cash flow from operating activities	140.3	71.7	-8.3	14.9	18.1	32.4
CAPEX	12.5	11.5	10.9	14.3	16.8	19.1
Payments for acquisitions	0.0	0.0	20.8	0.0	0.0	0.0
Financial investments	1.2	0.7	3.6	0.0	0.0	0.0
Income from asset disposals	0.0	-1.4	0.0	1.0	1.0	1.0
Cash flow from investing activities	-13.7	-13.7	-35.3	-13.3	-15.8	-18.1
Cash flow before financing	126.6	58.0	-43.7	1.6	2.3	14.4
Increase/decrease in debt position	-41.0	-39.6	-97.0	4.7	5.1	5.7
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	50.0	0.0	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Others	-2.3	-3.3	-3.7	0.0	0.0	0.0
Effects of exchange rate changes on cash	-2.3	-0.1	-3.9	0.0	0.0	0.0
Cash flow from financing activities	-43.3	7.1	-100.7	4.7	5.1	5.7
Increase/decrease in liquid assets	81.0	65.0	-148.3	6.3	7.5	20.0
Liquid assets at end of period	236.5	301.6	153.3	159.5	167.0	187.0
Key ratios (EUR m)	2020	2021	2022	2023e	2024e	<b>2025</b> e
P&L growth analysis	24.40/	11 10/	4.00/	7.00/	15 20/	10.60/
Sales growth	-21.4%	-11.4%	4.0%	7.2%	15.3%	12.6%
EBITDA growth	-2.6%	-24.5%	17.3%	42.0%	53.8%	50.8%
EBIT growth	-24.5%	-40.2%	10.8%	63.8%	81.2%	58.3%
EPS growth	-97.6%	-129.0%	1717.7%	-305.6%	182.2%	135.0%
Efficiency	0.47.7	200.4	070.0	000.4	204.0	204
Sales per employee	347.7	286.4	278.3	280.1	304.3	324.0
EBITDA per employee	63.2	59.7	64.4	74.3	87.5	99.8
No. employees (average)	663	713	763	813	863	913
Balance sheet analysis	4.0.404	000 =0/	224 424	000 101	222.224	
Avg. working capital / sales	143.4%	203.5%	201.1%	220.4%	209.8%	202.2%
Inventory turnover (sales/inventory)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a
Accounts receivable turnover	480.9	480.9	480.9	480.9	480.9	480.9
Accounts payable turnover	39.8	7.2	29.3	27.7	25.9	24.2
Cash flow analysis						
Free cash flow	127.8	60.2	-19.2	0.6	1.3	13.4
Free cash flow/sales	55.5%	29.5%	-9.1%	0.2%	0.5%	4.5%
FCF / net profit	27910.9%	neg.	neg.	4.0%	5.7%	40.6%
Capex / sales	5.9%	6.0%	6.8%	6.3%	6.4%	6.4%
Solvency						
Net debt	-61.5	-111.6	-97.7	-109.6	-134.6	-168.9
Net Debt/EBITDA	0.0	0.0	0.0	0.0	0.0	0.0
Dividend payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest paid / avg. debt	14.1%	16.2%	15.4%	25.3%	48.6%	48.9%
Returns						
ROCE	4.9%	3.7%	4.0%	5.7%	6.8%	7.9%
ROE	0.4%	-3.9%	4.6%	6.8%	10.3%	12.6%
Adjusted FCF yield	-313.9%	-38.3%	-42.4%	-44.2%	-45.2%	-42.7%
Dividend yield	0.0%	0.0%	0.0%	4.5%	0.0%	0.0%
DPS	0.0	0.0	0.0	0.1	0.0	0.0
EPS reported	0.02	-0.32	0.39	0.65	1.09	1.52
Average number of shares	21.6	21.6	21.6	21.6	21.6	21.6
Valuation ratios	21.0	21.0	21.0	21.0	21.0	21.0
P/BV	0.5	0.3	0.3	0.3	0.3	0.2
EV/sales	-0.1	-0.3	-0.2	-0.4	-0.3	-0.4
EV/EBITDA	-0.3	-1.3	-0.9	-1.4	-1.1	-1.3
=::	0.0		5.0		• • •	
EV/EBIT	-0.5	-2.0	-1.4	-2.0	-1.4	-1.6

Update - 17.11.2023



### **Disclosures**

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

### Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- (3) or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosures
Multitude SE	2

Historical target p	rice and rating changes for l	Multitude SE			
Company	Date	Analyst	Rating	Target Price	Close
Multitude SE	04.12.2022	Jarchow, Frederik	Buy	EUR 9.00	EUR 2.85

Update - 17.11.2023



#### 1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

#### 2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

### 3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

### 4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed com-

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

#### 5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

#### 6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

#### 7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

### 8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: <a href="https://www.nuways-ag.com">www.nuways-ag.com</a>

Date of publication creation: 17/11/2023 08:03 AM

Date of publication dissemination: 17/11/2023 08:03 AM

Update - 17.11.2023



### **Contacts**

## **NuWays AG**

Mittelweg 16-17 20148 Hamburg Germany +49 170 119 8648 info@nuways-ag.com www.nuways-ag.com



Christian Sandherr Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



**Philipp Sennewald** 

Analyst

philipp.sennewald@nuways-ag.com



**Henry Wendisch** 

Analyst

henry.wendisch@nuways-ag.com



Mark Schüssler

Analyst

mark-hendrik.schuessler@nuways-ag.com



Konstantin Völk

Analyst

konstantin.voelk@nuways-ag.com

Find us on Social Media

<u>Instagram</u>



Twitter/X



LinkedIn

